Evidence map›Paper›PMID 38259476›Full record

ReviewFrontiers in immunology2023

The immunomodulatory effects of mesenchymal stem cell-derived extracellular vesicles in Alzheimer's disease.

Yang Ye, Mingzhu Gao, Wentao Shi, Yan Gao, Yilu Li, Wenhui Yang, Xiaomin Zheng, Xiaojie Lu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Editorial: Application of stem cells in degenerative orthopedic diseases.Frontiers in cell and developmental biology · 2026
    Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Stem cell therapy offers new hope for the treatment of Alzheimer's disease.Frontiers in cell and developmental biology · 2025
    Review
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yang Ye *Research Institute for Reproductive Health and Genetic Diseases, Wuxi Maternity and Child Health Care Hospital, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Mingzhu Gao *Neuroscience Center, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Wentao ShiNeuroscience Center, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Yan GaoNeuroscience Center, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Yilu LiNeuroscience Center, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Wenhui YangNeuroscience Center, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Xiaomin ZhengResearch Institute for Reproductive Health and Genetic Diseases, Wuxi Maternity and Child Health Care Hospital, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Xiaojie LuNeuroscience Center, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Jiangnan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroinflammation has been identified as another significant pathogenic factor in Alzheimer's disease following Aβ amyloid deposition and tau protein hyperphosphorylation, activated in the central nervous system by glial cells in response to injury-related and pathogen-related molecular patterns. Moderate glial cell activity can be neuroprotective; however, excessive glial cell activation advances the pathology of Alzheimer's disease and is accompanied by structural changes in the brain interface, with peripheral immune cells entering the brain through the blood-brain barrier, creating a vicious circle. The immunomodulatory properties of mesenchymal stem cells (MSCs) are primarily conveyed through extracellular vesicles (EVs). MSC-EVs participate in chronic inflammatory and immune processes by transferring nucleic acids, proteins and lipids from the parent cell to the recipient cell, thus MSC-EVs retain their immunomodulatory capacity while avoiding the safety issues associated with living cell therapy, making them a promising focus for immunomodulatory therapy. In this review, we discuss the modulatory effects of MSC-EVs on Alzheimer's disease-associated immune cells and the mechanisms involved in their treatment of the condition. We have found a clinical trial of MSC-EVs in Alzheimer's disease treatment and outlined the challenges of this approach. Overall, MSC-EVs have the potential to provide a safe and effective treatment option for Alzheimer's disease by targeting neuroinflammation.

Indexed as

Alzheimer DiseaseExtracellular VesiclesMesenchymal Stem CellsHumansImmunomodulationNeuroinflammatory DiseasesAlzheimer’s diseasecentral nervous immune systemextracellular vesiclesmesenchymal stem cellsneuroinflammationperipheral immune system

Identifiers

PMID38259476
PMCPMC10800421
OpenAlexW4390665988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.